AIC284 - Innovative treatment against autoimmunity

AIC284 is an IL-2 mutein, especially engineered to maintain the activating effect of wildtype IL-2 on Treg cells and, at the same time, reduce the toxicity associated with systemic responses.  In vivo models of Type-I Diabetes, Systemic lupus erythematosus and Multiple sclerosis have proven AIC284 to be efficacious and safe. Given its unique profile, AIC284 has the potential to become the gold-standard treatment for all autoimmune diseases with underlying Treg cell deficiency.
AIC284 is open for sale of all relevant assets, including clinical grade drug product and a robust set of patents conferring broad global compound and formulation protection in the context of autoimmunity.
Interested in learning more about this unique approach against autoimmunity? Please contact: business(at)aicuris.com

If you have further questions regarding partnering of our projects please contact:

Arne Wilkens
Director Business Development &
Alliance Management
 
AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
 42117 Wuppertal
 
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: business(at)aicuris.com